Year: 2022

Assertio to Participate in October 2022 Investor Conferences

Written by Customer Service on October 12, 2022. Posted in Public Companies.

LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that management will participate at the following investor conference events during October 2022.Event: Windy City Roundup 2022Date: Thursday, October 13, 2022Presentation: 11:00 a.m. Central TimeLocation: Swissotel, Chicago Event: LD Micro Main Event XVDate: Tuesday, October 25, 2022Presentation: 10:30 a.m. Pacific TimeLive stream: https://me22.mysequire.com/ Location: Luxe Sunset Boulevard Hotel, Los AngelesAs part of the conference events, management will host one-on-one meetings throughout the day. For more information about scheduling a one-on-one meeting...

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

Written by Customer Service on October 12, 2022. Posted in Public Companies.

“Raising Capital for Psychedelic Endeavors” Panel Part of Conference’s Psychedelic Business Forum TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel serotonergic psychedelic drug development committed to innovating proprietary therapeutic solutions for mental health conditions, announced today that the Company’s President and CEO, Mr. Greg Mayes, will participate on a panel at this year’s Horizons Perspectives on Psychedelics conference, taking place at the New York Academy of Medicine in New York City. The panel session, titled, “Raising Capital for Psychedelic Endeavors,” is part of the conference’s Psychedelic Business Forum and will focus on how both companies and funds are raising capital to expand their business interests...

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

Written by Customer Service on October 12, 2022. Posted in Public Companies.

– 96-week findings support losmapimod as a disease-modifying therapy for FSHD – U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 – Industry Symposium on October 12, 2022, at 4:30pm EDT CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that new data from the open label extension (OLE) portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society (WMS) Hybrid Congress taking place October 11-15 in Halifax, Canada. Fulcrum will also host a symposium entitled “Measuring Progression in FSHD: Implications for Clinical Trials,”...

Marathon Gold Mobilizes Early Works at Valentine Gold Project

Written by Customer Service on October 12, 2022. Posted in Public Companies.

Photo Mobilization (left) for the replacement of the Victoria River Bridge (right)Photo Mobilization (left) for the replacement of the Victoria River Bridge (right)Photo 120 bed temporary camp installed (top). On-site laydown yard and fuel station (bottom)Photo 120 bed temporary camp installed (top). On-site laydown yard and fuel station (bottom)Photo Blasthole drill rigs (left). Commencement of grubbing at permanent camp location (right)Photo Blasthole drill rigs (left). Commencement of grubbing at permanent camp location (right)Photo Marathon’s permanent accommodation camp in storage in Badger, NLPhoto Construction of the Millertown off-site yard November 2021 (top). In use October 2022 (bottom)Photo Construction of the Millertown off-site yard November 2021 (top). In use October 2022 (bottom)Photo Caterpillar...

Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Written by Customer Service on October 12, 2022. Posted in Public Companies.

– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression – Supports combination development of toripalimab plus anti-TIGIT in NSCLC and other solid tumor indications REDWOOD CITY, Calif. and SHANGHAI, China, Oct. 12, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell lung cancer: a multi-center randomized phase 3 trial (CHOICE-01) in the Journal of Clinical Oncology. Toripalimab in combination with chemotherapy was associated...

MacDonald Mines Announces $1.5m Financing, Share Consolidation

Written by Customer Service on October 12, 2022. Posted in Public Companies.

TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — MacDonald Mines Exploration Ltd. (TSXV:BMK) (“MacDonald Mines” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement financing of units (the “Unit Offering”) and “flow-through” units (the “FT Offering”, and together with the Unit Offering, the “Offering”). The Offering will consist of (i) up to a maximum of up to $500,000 of Units at a (post-Consolidation – see below) price of $0.10 per Unit, and (ii) up to $1,000,000 of flow-through units (the “FT Units”) at a (post-Consolidation – see below) price of $0.13 per Unit. Each Unit will consist of one Class A common share (a “Common Share”) in the capital of the Company and one-half (1/2) of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”) of the Company....

Colliers completes investment in leading alternative investment manager

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

TORONTO and DENVER, Oct. 12, 2022 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) announced today the completion of its previously announced acquisition of a controlling interest in Versus Capital (“Versus”), a leading U.S. alternative real asset management firm with over $6.0 billion of assets under management. The acquisition of Versus accelerates Colliers’ global private wealth distribution capabilities and raises total assets under management to $87 billion. Colliers Contact Christian Mayer Chief Financial Officer | Global (416) 960-9500 About Colliers Colliers is a leading diversified professional services and investment management company. With operations in 63 countries, our 17,000 enterprising professionals work collaboratively to provide expert...

Chillers Market Size Worth USD 13.25 Billion, Globally, by 2026 at 4.1% CAGR

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

According to Fortune Business Insights, the global Chillers market size is projected to grow from USD 9.65 billion in 2018 to USD 13.25 billion in 2026, at CAGR of 4.1% during forecast period; Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The global Chillers Market was USD 9.65 billion in 2018. The global market size is expected gain momentum by reaching USD 13.25 billion by 2026, exhibiting a CAGR of 4.1% during the forecast period from 2019-2026. This information is provided by Fortune Business Insights, in its report, titled, “Chillers Market, 2019-2026.” According to our analysts, the factors such as growing demand for chillers from food & beverages, chemical, and, pharmaceutical industries will enable speedy expansion of the market.Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/chillers-market-101588Report...

InvestmentPitch Media Video Discusses Urbanimmersive’s Purchase Agreement for Acquisition of the Interests of Real Estate Photography Agency, HomeVisit, LLC from CoreLogic Solutions, LLC

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — Urbanimmersive Inc. (TSXV:UI) (OTCQB:UBMRF) has signed a final purchase agreement for the acquisition of all the interests of the real estate photography agency, HomeVisit, LLC from CoreLogic Solutions, LLC. HomeVisit, based in Chantilly, Virginia, is a leading provider of visual content marketing real estate solutions, including property listing photography, videography, 3D tours, drone imagery, printing services and other related services. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company, along with video comments from Ghislain Lemire, Urbanimmersive’s President & CEO. The video...

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Written by Customer Service on October 12, 2022. Posted in Public Companies.

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors. “We are pleased to welcome Kevin to the Decibel Board. He brings a wealth of biopharma experience, including guiding biotech companies through stages of increasing financial and operational maturity,” said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. “His appointment to the Board provides us with a critical strategic perspective as we continue to build a sustainable gene therapy company to develop innovating new medicines for hearing loss and balance disorders.” Mr. McLaughlin has more than 40 years of financial...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals